Remap Consulting are proud to announce that we are hosting two, 1 day market access training worksho...
Read moreThis study investigates NICE evaluations of new cancer indications and legacy CDF indications (not p...
Read morePaul Craddy is proud to be presenting at the Global Pharmaceutical Regulatory Affairs Summit in Prag...
Read moreOur training courses are designed to help your organization to understand market access and what it ...
Read moreObtaining market access at the right time and at an appropriate price has become more complex for ph...
Read moreIntroduction of a new German Act - Strengthening Pharmaceutical Supply in the Statutory Health Insur...
Read moreEMA has published Q&A document to prepare manufacturers for the UK's withdrawal from the EU with reg...
Read moreA one stop shop for joint advice between EMA, EUnetHTA and health technology assessment bodies - the...
Read moreGiven that the UK has formally announced its decision to leave the EU, what are the implications for...
Read moreMEAs are also known by other names such as risk-sharing agreements, value-added services, and result...
Read more